Inclusion Criteria:

- measurable metastatic adenocarcinoma of the colon or rectum

- no prior systemic therapy for metastatic disease

- adjuvant therapy must have been completed >/=12 months prior to recurrence, prior
radiotherapy permitted but must have been completed > 6 months prior to study entry

- must have tumor tissue available for EGFR and thymidine phosphorylase evaluation

- ECOG PS 0-1

- age >/= 18

- adequate organ function: WBC>/=3,000, ANC >/=1,500, platelets>/= 100,000, total
bilirubin /= 50mL/min

- negative pregnancy test w/in 72 hours of treatment for women of child bearing
potential

- ability to understand and willing to sign written ICF

- able to swallow and absorb oral medication

Exclusion Criteria:

- medical or psychiatric condition which would potentially pose risk to patient by
participation (i.e. but not limited to:uncontrolled hypertension, MI w/in 6
months,CNS disease, pregnancy or nursing)

- history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of
cervix) w/in 5 years

- surgical procedure (not including closed biopsy or access port placement), open
biopsy, significant traumatic injury w/in 28 days of registration or anticipation of
need for surgical procedure while on study, fine needle aspiration or core biopsy
w/in 7 days of registration

- urine protein:creatinine ration >/=1.0 at screening

- evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation)

- prior severe infusion reaction to MAB or allergic reaction to capecitabine or
oxaliplatin

- underlying neuropathy >/= grade 2

- TIA or CVA w/in 6 months